Elevance Health, Inc. $ELV Shares Sold by Crossmark Global Holdings Inc.

Key Points

• Crossmark Global Holdings reduced its Elevance Health stake by 6.7% in the third quarter, selling 3,580 shares and retaining 49,603 shares valued at approximately $19.3 million. Institutional investors collectively own 89.24% of the company.
• Analysts remain broadly positive, with 15 Buy ratings and eight Hold ratings producing a consensus “Moderate Buy” rating and an average price target of $441.71.
• Elevance reported stronger-than-expected quarterly results, earning $6.99 per share on $50.44 billion in revenue, and declared a quarterly dividend of $1.72 per share, equivalent to a 1.6% annualized yield.

Crossmark Global Holdings Inc. lowered its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 6.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,603 shares of the company's stock after selling 3,580 shares during the period. Crossmark Global Holdings Inc.'s holdings in Elevance Health were worth $19,287,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Canoe Financial LP boosted its position in shares of Elevance Health by 0.3% in the 3rd quarter. Canoe Financial LP now owns 364,526 shares of the company's stock worth $139,129,000 after buying an additional 1,022 shares in the last quarter. 365 WMG Private Fund I Primus Fund LLC acquired a new stake in Elevance Health in the 3rd quarter valued at about $930,000. Pinnacle Associates Ltd. grew its stake in Elevance Health by 7.4% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,922 shares of the company's stock valued at $1,136,000 after acquiring an additional 201 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its stake in Elevance Health by 94.0% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 332,778 shares of the company's stock valued at $129,391,000 after acquiring an additional 161,278 shares during the last quarter. Finally, Revisor Wealth Management LLC increased its holdings in Elevance Health by 6.6% during the 3rd quarter. Revisor Wealth Management LLC now owns 4,404 shares of the company's stock valued at $1,801,000 after acquiring an additional 274 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company's stock.

Analyst Ratings Changes

ELV has been the subject of a number of research reports. Raymond James Financial set a $450.00 target price on shares of Elevance Health in a research report on Tuesday, July 7th. Guggenheim upped their price target on shares of Elevance Health from $455.00 to $460.00 and gave the company a "buy" rating in a report on Monday, October 12th. TD Cowen increased their price target on shares of Elevance Health from $400.00 to $465.00 and gave the company a "buy" rating in a research report on Tuesday, July 14th. Weiss Ratings reiterated a "hold (c)" rating on shares of Elevance Health in a research report on Thursday, August 13th. Finally, Robert W. Baird raised their price objective on shares of Elevance Health from $331.00 to $393.00 and gave the stock a "neutral" rating in a research note on Thursday, July 16th. Fifteen analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $441.71.

Elevance Health Stock Performance

NYSE:ELV opened at $435.26 on Thursday. The firm has a 50 day simple moving average of $406.59 and a 200-day simple moving average of $389.52. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.52 and a quick ratio of 1.52. The firm has a market cap of $94.39 billion, a PE ratio of 19.34, a P/E/G ratio of 2.29 and a beta of 0.70. Elevance Health, Inc. has a 1-year low of $274.84 and a 1-year high of $450.69.

Elevance Health (NYSE:ELV - Get Free Report) last announced its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.71 by $2.28. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The firm had revenue of $50.44 billion for the quarter, compared to analyst estimates of $49.28 billion. During the same quarter last year, the business earned $6.03 earnings per share. Elevance Health's revenue was up .7% compared to the same quarter last year. On average, equities analysts expect that Elevance Health, Inc. will post 27.20 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health's dividend payout ratio is currently 30.58%.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Quarterly results exceeded expectations: Adjusted earnings were $6.99 per share versus the roughly $4.66–$4.71 consensus estimate, while revenue reached $50.44 billion, above expectations of about $49.22 billion. Earnings also increased from $6.03 per share a year earlier. Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: 2026 outlook was raised: Management lifted its underlying earnings baseline to at least $26.75 per share, citing disciplined expense management and better medical-cost performance. Elevance also expects at least 12% adjusted EPS growth in 2027 from the higher earnings base. Elevance lifts 2026 profit forecast on better medical cost management
• Positive Sentiment: Carelon remained a growth driver: Strength in the services business helped offset pressure elsewhere, supporting management’s confidence in future growth. Elevance named Jeff Park president of Carelon, effective December 1, to lead its next expansion phase. Elevance Health Names Jeff Park President of Carelon
• Neutral Sentiment: Elevance declared a quarterly dividend of $1.72 per share, or $6.88 annualized, representing a yield of approximately 1.6%. The payout supports shareholder returns but is unlikely to be the primary near-term trading catalyst.
• Negative Sentiment: Membership pressure remains a concern: The earnings beat occurred despite declining medical membership, increasing investor focus on enrollment trends and the company’s ability to sustain growth.
• Negative Sentiment: Although cost management improved, Elevance operates on a thin net margin, and continued medical-cost inflation or weaker enrollment could limit the benefit of the raised forecast. The shares have also recently traded near a 52-week high, potentially increasing profit-taking risk.

Elevance Health Profile

Elevance Health, Inc NYSE: ELV is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.